Metabotropic Glutamate Receptor 5 Negative Modulation in Phase I Clinical Trial: Potential Impact of Circadian Rhythm on the Neuropsychiatric Adverse Reactions—Do Hallucinations Matter?

Table 3

Onset and end of (pseudo) hallucinations reported from/observed in 11 subjects during the course of the clinical trial.

Subject number	Dosing times*	Number of episodes	Onset*	End*
2	08:05 and 20:05	1	C: 00:15	00:45
3	08:10 and 20:10	1	C: 01:30	02:00
5	08:20 and 20:20	1	C: 23:30	01:30
6	08:25 and 20:25	2	C: 01:07	02:00
			C: 01:30	08:00
8	08:00 and 20:00	1	C: 08:45	08:55
9	08:00 and 20:00	1	C: 23:00	23:30
10	08:05 and 20:05	1	C: 01:00	02:30
13	08:20 and 20:20	1	C: 00:30	00:35
15	08:15 and 20:15	3	S: 09:50	11:00
			C: 00:00	03:00
16	08:25 and 20:25	11	C: 02:00	03:00
			C: 00:00	07:30
			C: 00:00	02:30
			C: 23:30	08:00
			S: 22:00	08:00
			S: 21:30	03:30
			S: 21:00	09:00
			S: 21:15	07:29
			S: 21:30	08:00
			S: 21:25	07:30
			S: 21:30	23:00
17	08:30 and 20:30	1	C: 00:20	03:30

∗Clock time (h:minutes); C: complex (pseudo) hallucination; S: simple (pseudo) hallucination. Insomnia: 11–19; 24–28.